Why BIND Therapeutics Is Up Big (And There's More To Watch On The Horizon)

BIND Therapeutics Inc BIND is up on Thursday morning after reporting positive news at the close Wednesday.

The company reported results of its ongoing Phase 2 study of BIND-014 in non-small cell lung cancer in the "once every three weeks" treatment arm.

On November 19, the company announced that its Phase 2 study for BIND-014 met primary objectives. However, that data then was not seen as promising, and the stock fell about 50 percent over the course of the next month.

Bind also announced top-line data from its Phase 2 trial with BIND-014 in castration resistant prostate cancer (mCRPC). The trial demonstrated a median rPFS of 8.1 months and 60 percent of the patients had a rPFS of 6 months or greater.

Related Link: NPS Pharma: Here's What Investors Are Watching

Bind's CEO stated: “The efficacy and tolerability profile of BIND-014 in mCRPC, particularly in this later stage population with prior androgen inhibitor treatment, serve to reinforce the promise of the Accurin platform. Given the rapidly evolving prostate cancer treatment landscape, we believe that there are more promising opportunities at this time for the Accurin platform within our development portfolio and are excited about the opportunities for BIND-014 in NSCLC and other difficult to treat areas.”

The company is planning on presenting this data at an upcoming medical meeting.

Worth noting: Bind also announced it is initiating Phase 2 clinical trials with BIND-014 in cholangiocarcinoma, cervical cancer, bladder cancer, and head and neck cancer.

Image credit: Bind